ArticleInternational urology and nephrology2026

Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis.

Koichi Nishimura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.